Published in Biotech Business Week, July 18th, 2005
A pilot bioequivalence study has already been completed and scale up will begin shortly. After scale up and completion of a successful pivotal bioequivalence study for the product, an abbreviated new drug application will be filed with the U.S. Food and Drug Administration.
Dr. Isa Odidi, chairman, CEO, and co-chief...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.